The Medicines Company
8 Sylvan Way
About The Medicines Company
The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.
500 articles with The Medicines Company
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
1/10/2020The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
12/25/2019To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
“We are excited about entering into an agreement to acquire The Medicines Company as inclisiran is a potentially transformational medicine that reimagines the treatment of atherosclerotic heart disease and familial hypercholesterolemia,” said Vas Narasimhan, chief executive officer of Novartis.
11/25/2019As usual, it was a busy week for clinical trial updates. Here’s a look.
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion
The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price
11/19/2019Amidst rumors that Novartis might be interested in an acquisition, The Medicines Company announced data from ORION-10, the second of three 19-month Phase III trials of inclisiran for lowering cholesterol.
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
Inclisiran achieved 50% LDL-C lowering with time-adjusted reductions of 45% sustained over 18 months of treatment in patients with heterozygous familial hypercholesterolemia (HeFH)
The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
Inclisiran achieved 58% LDL-C lowering with time-adjusted reductions of 56% sustained over 18 months of treatment in patients with atherosclerotic cardiovascular disease (ASCVD)
The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019
The Medicines Company announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science sessions at the American Heart Association Scientific Sessions 2019, November 16-18, in Philadelphia.
The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran
Inclisiran’s pivotal Phase 3 LDL-C lowering clinical trials program successfully completed, and each study met all primary and secondary endpoints
Wednesday, October 30, 2019 at 8:30 a.m. EDT to discuss its third quarter 2019 financial results and operational developments.
9/30/2019It was a moderately busy week for clinical trial news. Here’s a look.
The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients
The Medicines Company announced positive topline results for the ORION-9 Phase 3 clinical study in patients with Heterozygous Familial Hypercholesterolemia.
The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients
The Medicines Company announced positive topline results for the ORION-10 Phase 3 clinical study in patients with atherosclerotic cardiovascular disease, successfully completing the pivotal Phase 3 LDL-cholesterol lowering clinical trials for inclisiran.
The Medicines Company's Inclisiran Treats Cholesterol Effectively with No Liver or Renal Side Eff...
9/25/2019Inclisiran is the first and only drug for cholesterol in the siRNA class.
9/9/2019Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
9/3/2019Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
The Medicines Company announced the presentation of results from ORION-11, its first pivotal Phase 3 clinical study of inclisiran, an investigational twice-yearly therapy to reduce low-density lipoprotein cholesterol and the first and only cholesterol-lowering therapy in the siRNA class.